Sfoglia per Autore
Phenotypic and molecular features of acute promyelocytic leukemia patients developing retinoic acid syndrome
2007 M., Breccia; R., Latagliata; I., Carmosino; L., Cannella; M. S., De Propris; Guarini, Anna; D., Diverio; A., Frustaci; Stefanizzi, Caterina; Cimino, Giuseppe; LO COCO, Francesco
Early hospital discharge with oral antimicrobial therapy in patients with hematologic malignancies and low-risk febrile neutropenia
2007 Corrado, Girmenia; Eleonora, Russo; Ida, Carmosino; Massimo, Breccia; Francesco, Dragoni; Roberto, Latagliata; Sergio, Mecarocci; Salvatore Giacomo, Morano; Stefanizzi, Caterina; Alimena, Giuliana
Nilotinib can override dasatinib resistance in chronic myeloid leukemia patients with secondary resistance to imatinib first-line therapy
2007 Massimo, Breccia; Laura, Cannella; Mauro, Nanni; Stefanizzi, Caterina; Alimena, Giuliana
Biologic and clinical significance of CD34 expression in acute promyelocytic leukemia
2007 M., Breccia; R., Latagliata; I., Carmosino; L., Cannella; Guarini, Anna; M. S., De Propris; D., Diverio; A., Frustaci; Stefanizzi, Caterina; Cimino, Giuseppe; LO COCO, Francesco
Rituximab associated to imatinib for coexisting therapy-related chronic myeloid leukemia and relapsed non-Hodgkin lymphoma.
2008 Breccia, M; Martelli, Maurizio; Cannella, L; E., Russo; Finolezzi, E; Stefanizzi, Caterina; Levi, A; Frustaci, A; Alimena, Giuliana
Isolated thrombocytosis as first sign of chronic myeloid leukemia with e6a2 BCR/ABL fusion transcript, JAK2 negativity and complete response to imatinib
2008 Massimo, Breccia; Laura, Cannella; Daniela, Diverio; P., Stregoni; Mauro, Nanni; Stefanizzi, Caterina; Fiammetta, Natalino; Sergio, Mecarocci; Alimena, Giuliana
Differences in hematological and non-hematological toxicity during treatment with imatinib in patients with early and late chronic phase chronic myeloid leukemia
2008 Massimo, Breccia; Stefanizzi, Caterina; Laura, Cannella; Roberto, Latagliata; Anna Maria, Frustaci; Ida, Carmosino; Michelina, Santopietro; Alimena, Giuliana
Fasting glucose improvement under dasatinib treatment in an accelerated phase chronic myeloid leukemia patient unresponsive to imatinib and nilotinib
2008 M., Breccia; Muscaritoli, Maurizio; L., Cannella; Stefanizzi, Caterina; A., Frustaci; Alimena, Giuliana
Pregnancy in patients with myelodysplastic syndromes (MDS)
2008 P., Volpicelli; R., Latagliata; M., Breccia; I., Carmosino; Stefanizzi, Caterina; Napoleone, Laura; F., Vozella; A., Levi; F., Natalino; Alimena, Giuliana
Chronic myelomonocytic leukemia with antecedent refractory anemia with excess blasts: Further evidence for the arbitrary nature of current classification systems
2008 M., Breccia; L., Cannella; A., Frustaci; Stefanizzi, Caterina; G. M., D'Elia; Alimena, Giuliana
Cardiac events in imatinib mesylate-treated chronic myeloid leukemia patients: A single institution experience
2008 Massimo, Breccia; Laura, Cannella; Annamaria, Frustaci; Stefanizzi, Caterina; Anna, Levi; Alimena, Giuliana
Unusual association of paroxysmal cold hemoglobinuria as the first sign of disease in myelodysplastic patient
2009 Stefanizzi, Caterina; Massimo, Breccia; Michelina, Santopietro; Serelina, Coluzzi; Laura, Cannella; Girelli, Gabriella; Alimena, Giuliana
Isolated molecular relapse in FIP1L1-PDGFRalpha hypereosinophilic syndrome after discontinuation and single weekly dose of imatinib: need of quantitative molecular procedures to modulate imatinib dose.
2009 Breccia, M; Cilloni, D; Cannella, L; Stefanizzi, Caterina; Tafuri, Agostino; Fama, A; Santopietro, M; Saglio, G; Alimena, Giuliana
Dasatinib overcomes imatinib and nilotinib failure in Philadelphia chromosome positive chronic myeloid leukemia with different mechanisms of resistance
2009 Laura, Cannella; Massimo, Breccia; Stefanizzi, Caterina; Napoleone, Laura; Michela, Santopietro; Alimena, Giuliana
Sequential development of mutant clones in an imatinib resistant chronic myeloid leukemia patient following sequential treatment with multiple tyrosine kinase inhibitors: an emerging problem?
2009 Frustaci, Am; Cannella, L; Soverini, S; Stefanizzi, Caterina; Federico, V; Grammatico, S; Santopietro, M; Alimena, Giuliana
Platelet count is an independent prognostic factor in myelodysplastic syndromes considered as low risk by French-American-British and World Health Organisation classifications.
2009 Breccia, M; D'Elia, Gm; Cannella, L; Stefanizzi, Caterina; Fama, A; Federico, V; Santopietro, M; Alimena, Giuliana
Comorbidities and FLT3-ITD Abnormalities as Independent Prognostic Indicators of Survival in Elderly Acute Myeloid Leukaemia Patients
2009 Massimo, Breccia; Anna Maria, Frustaci; Laura, Cannella; Stefanizzi, Caterina; Roberto, Latagliata; Claudio, Cartoni; Daniela, Diverio; Guarini, Anna; R., Nanni; Angela, Rago; Cimino, Giuseppe; Alimena, Giuliana
Efficacy of dasatinib in a chronic myeloid leukemia patient with disease molecular relapse and chronic GVHD after haploidentical BMT: AN IMMUNOMODULATORY EFFECT?
2009 Breccia, M; Cannella, L; Stefanizzi, Caterina; Carotti, A; Santopietro, M; Alimena, Giuliana
WPSS versus simplified myelodysplastic syndrome risk score: Which is the best tool for prediction of survival in myelodysplastic patients?
2009 Breccia, M; Cannella, L; Stefanizzi, Caterina; Latagliata, R; Fama, A; Santopietro, M; Alimena, Giuliana
Analysis of prognostic factors in patients with refractory anemia with excess of blasts (RAEB) reclassified according to WHO proposal
2009 M., Breccia; R., Latagliata; L., Cannella; I., Carmosino; R., De Cuia; A., Frustaci; Stefanizzi, Caterina; M., Santopietro; Alimena, Giuliana
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Phenotypic and molecular features of acute promyelocytic leukemia patients developing retinoic acid syndrome | 2007 | M., Breccia; R., Latagliata; I., Carmosino; L., Cannella; M. S., De Propris; Guarini, Anna; D., Diverio; A., Frustaci; Stefanizzi, Caterina; Cimino, Giuseppe; LO COCO, Francesco | |
| Early hospital discharge with oral antimicrobial therapy in patients with hematologic malignancies and low-risk febrile neutropenia | 2007 | Corrado, Girmenia; Eleonora, Russo; Ida, Carmosino; Massimo, Breccia; Francesco, Dragoni; Roberto, Latagliata; Sergio, Mecarocci; Salvatore Giacomo, Morano; Stefanizzi, Caterina; Alimena, Giuliana | |
| Nilotinib can override dasatinib resistance in chronic myeloid leukemia patients with secondary resistance to imatinib first-line therapy | 2007 | Massimo, Breccia; Laura, Cannella; Mauro, Nanni; Stefanizzi, Caterina; Alimena, Giuliana | |
| Biologic and clinical significance of CD34 expression in acute promyelocytic leukemia | 2007 | M., Breccia; R., Latagliata; I., Carmosino; L., Cannella; Guarini, Anna; M. S., De Propris; D., Diverio; A., Frustaci; Stefanizzi, Caterina; Cimino, Giuseppe; LO COCO, Francesco | |
| Rituximab associated to imatinib for coexisting therapy-related chronic myeloid leukemia and relapsed non-Hodgkin lymphoma. | 2008 | Breccia, M; Martelli, Maurizio; Cannella, L; E., Russo; Finolezzi, E; Stefanizzi, Caterina; Levi, A; Frustaci, A; Alimena, Giuliana | |
| Isolated thrombocytosis as first sign of chronic myeloid leukemia with e6a2 BCR/ABL fusion transcript, JAK2 negativity and complete response to imatinib | 2008 | Massimo, Breccia; Laura, Cannella; Daniela, Diverio; P., Stregoni; Mauro, Nanni; Stefanizzi, Caterina; Fiammetta, Natalino; Sergio, Mecarocci; Alimena, Giuliana | |
| Differences in hematological and non-hematological toxicity during treatment with imatinib in patients with early and late chronic phase chronic myeloid leukemia | 2008 | Massimo, Breccia; Stefanizzi, Caterina; Laura, Cannella; Roberto, Latagliata; Anna Maria, Frustaci; Ida, Carmosino; Michelina, Santopietro; Alimena, Giuliana | |
| Fasting glucose improvement under dasatinib treatment in an accelerated phase chronic myeloid leukemia patient unresponsive to imatinib and nilotinib | 2008 | M., Breccia; Muscaritoli, Maurizio; L., Cannella; Stefanizzi, Caterina; A., Frustaci; Alimena, Giuliana | |
| Pregnancy in patients with myelodysplastic syndromes (MDS) | 2008 | P., Volpicelli; R., Latagliata; M., Breccia; I., Carmosino; Stefanizzi, Caterina; Napoleone, Laura; F., Vozella; A., Levi; F., Natalino; Alimena, Giuliana | |
| Chronic myelomonocytic leukemia with antecedent refractory anemia with excess blasts: Further evidence for the arbitrary nature of current classification systems | 2008 | M., Breccia; L., Cannella; A., Frustaci; Stefanizzi, Caterina; G. M., D'Elia; Alimena, Giuliana | |
| Cardiac events in imatinib mesylate-treated chronic myeloid leukemia patients: A single institution experience | 2008 | Massimo, Breccia; Laura, Cannella; Annamaria, Frustaci; Stefanizzi, Caterina; Anna, Levi; Alimena, Giuliana | |
| Unusual association of paroxysmal cold hemoglobinuria as the first sign of disease in myelodysplastic patient | 2009 | Stefanizzi, Caterina; Massimo, Breccia; Michelina, Santopietro; Serelina, Coluzzi; Laura, Cannella; Girelli, Gabriella; Alimena, Giuliana | |
| Isolated molecular relapse in FIP1L1-PDGFRalpha hypereosinophilic syndrome after discontinuation and single weekly dose of imatinib: need of quantitative molecular procedures to modulate imatinib dose. | 2009 | Breccia, M; Cilloni, D; Cannella, L; Stefanizzi, Caterina; Tafuri, Agostino; Fama, A; Santopietro, M; Saglio, G; Alimena, Giuliana | |
| Dasatinib overcomes imatinib and nilotinib failure in Philadelphia chromosome positive chronic myeloid leukemia with different mechanisms of resistance | 2009 | Laura, Cannella; Massimo, Breccia; Stefanizzi, Caterina; Napoleone, Laura; Michela, Santopietro; Alimena, Giuliana | |
| Sequential development of mutant clones in an imatinib resistant chronic myeloid leukemia patient following sequential treatment with multiple tyrosine kinase inhibitors: an emerging problem? | 2009 | Frustaci, Am; Cannella, L; Soverini, S; Stefanizzi, Caterina; Federico, V; Grammatico, S; Santopietro, M; Alimena, Giuliana | |
| Platelet count is an independent prognostic factor in myelodysplastic syndromes considered as low risk by French-American-British and World Health Organisation classifications. | 2009 | Breccia, M; D'Elia, Gm; Cannella, L; Stefanizzi, Caterina; Fama, A; Federico, V; Santopietro, M; Alimena, Giuliana | |
| Comorbidities and FLT3-ITD Abnormalities as Independent Prognostic Indicators of Survival in Elderly Acute Myeloid Leukaemia Patients | 2009 | Massimo, Breccia; Anna Maria, Frustaci; Laura, Cannella; Stefanizzi, Caterina; Roberto, Latagliata; Claudio, Cartoni; Daniela, Diverio; Guarini, Anna; R., Nanni; Angela, Rago; Cimino, Giuseppe; Alimena, Giuliana | |
| Efficacy of dasatinib in a chronic myeloid leukemia patient with disease molecular relapse and chronic GVHD after haploidentical BMT: AN IMMUNOMODULATORY EFFECT? | 2009 | Breccia, M; Cannella, L; Stefanizzi, Caterina; Carotti, A; Santopietro, M; Alimena, Giuliana | |
| WPSS versus simplified myelodysplastic syndrome risk score: Which is the best tool for prediction of survival in myelodysplastic patients? | 2009 | Breccia, M; Cannella, L; Stefanizzi, Caterina; Latagliata, R; Fama, A; Santopietro, M; Alimena, Giuliana | |
| Analysis of prognostic factors in patients with refractory anemia with excess of blasts (RAEB) reclassified according to WHO proposal | 2009 | M., Breccia; R., Latagliata; L., Cannella; I., Carmosino; R., De Cuia; A., Frustaci; Stefanizzi, Caterina; M., Santopietro; Alimena, Giuliana |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile